Skip to main content
AAPL-0.40%MSFT+0.77%NVDA+4.12%GOOGL-1.24%AMZN+0.82%TSM-3.68%SPCX+3.16%AVGO+2.46%META+0.58%TSLA+0.88%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+4.22%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.99%0700.HK-3.69%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.84%UNH-5.42%ORCL-3.38%3988.HK-0.63%BAC-1.28%HD-2.45%GE+0.38%0857.HK-0.38%1816.HK-2.30%1288.HK-0.86%0005.HK-1.42%PM-0.85%NVS-0.67%HSBA.L-1.95%MS-1.10%INTC-0.54%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.68%NZDJPY-0.63%AUDUSD-0.58%NZDUSD-0.52%GBPAUD+0.51%GBPNZD+0.47%EURJPY-0.43%GBPTRY+0.41%CHFJPY-0.39%CADJPY-0.35%AUDCAD-0.34%GBPHKD+0.32%USDCHF+0.32%EURUSD-0.31%AUDCHF-0.29%NZDCAD-0.29%GBPMXN-0.28%EURAUD+0.27%GBPCHF+0.26%EURGBP-0.25%USDCAD+0.24%NZDCHF-0.23%EURNZD+0.21%USDTHB-0.19%GBPCAD+0.18%GBPJPY-0.17%USDILS+0.16%USDTRY+0.16%USDJPY-0.12%USDDKK+0.10%USDCNH-0.10%CHFSGD-0.09%EURSGD-0.09%EURCNH-0.08%SGDJPY+0.08%NZDMXN+0.08%AUDNZD-0.06%EURCAD-0.06%CADCHF+0.06%NZDSGD+0.05%GBPUSD-0.05%USDMXN+0.04%USDCOP-0.04%AUDNOK+0.04%GBPSGD-0.02%AUDSGD-0.02%USDZAR+0.02%USDHKD+0.01%USDSGD+0.01%EURCHF+0.01%GBPZAR0.00%NOKJPY0.00%USDSEK0.00%EURCZK0.00%USDPLN0.00%EURHKD0.00%EURPLN0.00%EURNOK0.00%CHFNOK0.00%EURZAR0.00%EURSEK0.00%AUDDKK0.00%CHFSEK0.00%USDNOK0.00%EURDKK0.00%PLNJPY0.00%XAGUSD-0.75%GAGUSD-0.75%XAUUSD-0.72%GAUUSD-0.70%XPTUSD-0.55%XNGUSD+0.44%HG1-0.18%USOIL-0.08%COTTON0.00%COFFEE0.00%COCOA0.00%UKOIL0.00%BTCUSD-0.17%ETHUSD+58.05%USDTUSD-0.01%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+0.92%ZECUSDT+6.84%XMRUSDT+3.30%DOGEUSD+59.04%LINKUSD+1.50%XLMUSD+2.98%BCHUSDT+1.44%LTCUSD+50.36%UNIUSD+2.32%TONUSD+63.46%SUIUSD+2.15%HBARUSDT+1.08%TAOUSDT+3.16%AAVEUSD+3.68%ONDOUSDT+0.82%ICPUSDT-7.82%DOTUSDT+1.18%WLDUSDT+1.85%ARBUSDT+0.44%INJUSDT+6.73%ATOMUSDT-0.47%STXUSDT+5.51%PYTHUSDT+1.82%TIAUSDT+0.63%FETUSDT+0.34%SEIUSDT+1.04%JUPUSDT+8.18%GRTUSDT+4.68%OPUSDT-2.36%IOTAUSDT+3.09%POLUSDT+4.01%WIFUSDT+1.17%AXSUSDT+1.56%EOSUSDT+2.59%FARTCOINUSDT-1.44%IMXUSDT+2.00%GALAUSDT-1.23%DYDXUSDT+2.20%ORDIUSDT+0.10%NOTUSDT+1.77%RONINUSDT+2.00%AAPL-0.40%MSFT+0.77%NVDA+4.12%GOOGL-1.24%AMZN+0.82%TSM-3.68%SPCX+3.16%AVGO+2.46%META+0.58%TSLA+0.88%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+4.22%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.99%0700.HK-3.69%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.84%UNH-5.42%ORCL-3.38%3988.HK-0.63%BAC-1.28%HD-2.45%GE+0.38%0857.HK-0.38%1816.HK-2.30%1288.HK-0.86%0005.HK-1.42%PM-0.85%NVS-0.67%HSBA.L-1.95%MS-1.10%INTC-0.54%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.68%NZDJPY-0.63%AUDUSD-0.58%NZDUSD-0.52%GBPAUD+0.51%GBPNZD+0.47%EURJPY-0.43%GBPTRY+0.41%CHFJPY-0.39%CADJPY-0.35%AUDCAD-0.34%GBPHKD+0.32%USDCHF+0.32%EURUSD-0.31%AUDCHF-0.29%NZDCAD-0.29%GBPMXN-0.28%EURAUD+0.27%GBPCHF+0.26%EURGBP-0.25%USDCAD+0.24%NZDCHF-0.23%EURNZD+0.21%USDTHB-0.19%GBPCAD+0.18%GBPJPY-0.17%USDILS+0.16%USDTRY+0.16%USDJPY-0.12%USDDKK+0.10%USDCNH-0.10%CHFSGD-0.09%EURSGD-0.09%EURCNH-0.08%SGDJPY+0.08%NZDMXN+0.08%AUDNZD-0.06%EURCAD-0.06%CADCHF+0.06%NZDSGD+0.05%GBPUSD-0.05%USDMXN+0.04%USDCOP-0.04%AUDNOK+0.04%GBPSGD-0.02%AUDSGD-0.02%USDZAR+0.02%USDHKD+0.01%USDSGD+0.01%EURCHF+0.01%GBPZAR0.00%NOKJPY0.00%USDSEK0.00%EURCZK0.00%USDPLN0.00%EURHKD0.00%EURPLN0.00%EURNOK0.00%CHFNOK0.00%EURZAR0.00%EURSEK0.00%AUDDKK0.00%CHFSEK0.00%USDNOK0.00%EURDKK0.00%PLNJPY0.00%XAGUSD-0.75%GAGUSD-0.75%XAUUSD-0.72%GAUUSD-0.70%XPTUSD-0.55%XNGUSD+0.44%HG1-0.18%USOIL-0.08%COTTON0.00%COFFEE0.00%COCOA0.00%UKOIL0.00%BTCUSD-0.17%ETHUSD+58.05%USDTUSD-0.01%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+0.92%ZECUSDT+6.84%XMRUSDT+3.30%DOGEUSD+59.04%LINKUSD+1.50%XLMUSD+2.98%BCHUSDT+1.44%LTCUSD+50.36%UNIUSD+2.32%TONUSD+63.46%SUIUSD+2.15%HBARUSDT+1.08%TAOUSDT+3.16%AAVEUSD+3.68%ONDOUSDT+0.82%ICPUSDT-7.82%DOTUSDT+1.18%WLDUSDT+1.85%ARBUSDT+0.44%INJUSDT+6.73%ATOMUSDT-0.47%STXUSDT+5.51%PYTHUSDT+1.82%TIAUSDT+0.63%FETUSDT+0.34%SEIUSDT+1.04%JUPUSDT+8.18%GRTUSDT+4.68%OPUSDT-2.36%IOTAUSDT+3.09%POLUSDT+4.01%WIFUSDT+1.17%AXSUSDT+1.56%EOSUSDT+2.59%FARTCOINUSDT-1.44%IMXUSDT+2.00%GALAUSDT-1.23%DYDXUSDT+2.20%ORDIUSDT+0.10%NOTUSDT+1.77%RONINUSDT+2.00%

Amgen posts positive Phase 3 data in Sjögren's

NEWS

November 11, 2026 at 13:48 UTC

3 min read
Unbranded biologic drug vials in a clinical lab illustrating positive Phase 3 Sjögren’s trial results for AMGN

Key Points

  • 01Amgen (AMGN)’s Phase 3 OASIZ-301 trial of dazodalibep met its primary endpoint in Sjögren’s disease
  • 02Both monthly and quarterly dosing regimens reduced ESSDAI scores more than placebo at week 48
  • 03Monthly dosing showed significant improvements in patient‑reported dryness versus placebo
  • 04Safety profile was balanced across groups, with mostly mild to moderate common adverse events

Amgen reports positive Phase 3 results for dazodalibep

Amgen (AMGN) released full results from the Phase 3 OASIZ-301 trial of dazodalibep in Sjögren's disease on November 11, 2026, confirming that the study met its primary endpoint. Both evaluated dosing regimens demonstrated statistically significant reductions in systemic disease activity at week 48 compared with placebo, as measured by the ESSDAI score. The trial enrolled 648 patients with moderate-to-severe systemic disease activity and compared 1,500 mg every four weeks and 3,000 mg every 12 weeks against placebo over 48 weeks.

The 1,500 mg every four weeks regimen produced a least-squares mean reduction of 5.6 points from baseline in ESSDAI score, versus a 3.8-point reduction for placebo, a difference of 1.8 points with an adjusted p-value below 0.001. The 3,000 mg every 12 weeks regimen showed a 5.2-point reduction, 1.4 points more than placebo, with an adjusted p-value of 0.010. A treatment effect was observed as early as week 4 and was sustained through week 48 for both regimens.

Efficacy on symptoms and responder outcomes

Beyond the primary endpoint, OASIZ-301 showed benefits on key symptoms that matter to patients with Sjögren's disease. At week 48, the 1,500 mg every four weeks regimen significantly improved patient-reported dryness compared with placebo. The placebo-adjusted least-squares mean differences in change from baseline were –1.17 points on the dryness domain of the ESSPRI index and –0.93 points on the dryness domain of the DASPRI diary, with adjusted p-values below 0.001 for both measures.

A greater proportion of patients treated with dazodalibep achieved ESSDAI improvements of at least 3, 5 or 7 points compared with placebo, indicating more patients reached clinically meaningful reductions in systemic disease activity. Dazodalibep also showed consistent improvements across ESSDAI domain-level responses, including constitutional, glandular, articular, lymphadenopathy, cutaneous and biological domains. More patients on dazodalibep met the STAR composite response criteria at week 48 than on placebo, and treated patients showed greater increases in stimulated salivary flow, an objective measure of oral dryness.

Safety profile and ongoing development program

The safety profile of dazodalibep in OASIZ-301 was generally balanced across the treatment and placebo groups. Rates of serious adverse events and discontinuations due to adverse events were similar between arms. The most common adverse events occurring in at least 5% of patients and more frequently with dazodalibep than placebo were nasopharyngitis, urinary tract infection, hypertension and infusion-related reactions, which were generally mild to moderate in severity.

Dazodalibep is a potential first-in-class CD40L antagonist fusion protein designed to disrupt immune activation pathways relevant to Sjögren's disease. In addition to OASIZ-301, Amgen (AMGN) is running the Phase 3 OASIZ-303 trial in patients with high symptom burden and low systemic disease activity, as well as OASIZ-304, an open-label extension assessing long-term safety and tolerability in participants from the Phase 3 studies. These programs aim to characterize dazodalibep's benefit-risk profile across different Sjögren's disease populations.

Key Takeaways

  • 01OASIZ-301 provides statistically robust evidence that dazodalibep reduces systemic disease activity in moderate-to-severe Sjögren’s disease.
  • 02Monthly dosing of dazodalibep shows simultaneous benefits on systemic inflammation and patient‑reported dryness, addressing both clinical and symptomatic aspects of the disease.
  • 03Balanced safety outcomes and largely mild to moderate common adverse events support continued late‑stage development and long‑term evaluation of the therapy in broader patient groups.

Amgen posts positive Phase 3 data in Sjögren's | Trading Dashboard